Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Nesrin Dilbaz. (2015) New Targets for the Management of Schizophrenia. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 25:4, pages 407-428.
Read now
Read now
S. Ganesan, V. Agambaram, F. Randeree, I. Eggens, K. Huizar & D. Meuliend. (2008) Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Current Medical Research and Opinion 24:1, pages 21-32.
Read now
Read now
Michael Riedel, Norbert Müller, Martin Strassnig, Ilja Spellmann, Emanuel Severus & Hans-Jürgen Möller. (2007) Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatric Disease and Treatment 3:2, pages 219-235.
Read now
Read now
Frank Beer, Hartmut Heinrich, Stephan Springer, Ulrich Rüth & Franz Joseph Freisleder. (2007) Quetiapine in the treatment of psychotic adolescents: A case series of 23 patients with severe early onset psychosis. The World Journal of Biological Psychiatry 8:1, pages 38-41.
Read now
Read now
Juan Gibert, José Giner, Julio Bobes, Mónica Tafalla, Santiago Herranz, Carmen Ovejero, Fernando Rico-Villademoros, Juan Gibert, José Giner, Julio Bobes, Mónica Tafalla, Santiago Herranz, Carmen Ovejero & Fernando Rico-Villademoros. (2007) The “Seroquel” Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia. International Journal of Psychiatry in Clinical Practice 11:3, pages 222-232.
Read now
Read now
Jonathan S. E. Hellewell. (2007) Quetiapine demonstrates good tolerability and is associated with improvements in extrapyramidal symptoms in patients with schizophrenia switched from other antipsychotics: results of a naturalistic study. International Journal of Psychiatry in Clinical Practice 11:2, pages 112-122.
Read now
Read now
Martin Lambert, Paul-Egbert Reimitz & Dieter Naber. (2006) Effectiveness, tolerability and subjective well-being in patients receiving quetiapine: findings of a post-marketing surveillance study in schizophrenia. International Journal of Psychiatry in Clinical Practice 10:3, pages 204-212.
Read now
Read now
Peter Falkai, Thomas Wobrock, Jeffrey Lieberman, Birte Glenthoj, Wagner F. Gattaz, Hans-Jürgen Möller, WFSBP Task Force on Treatment Guidelines for Schizophrenia, Peter Falkai, Thomas Wobrock, Jeffrey Lieberman, Birte Glenthoj, Wagner F. Gattaz, Hans-Jürgen Möller & WFSBP Task Force on Treatment Guidelines for Schizophrenia. (2005) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. The World Journal of Biological Psychiatry 6:3, pages 132-191.
Read now
Read now
Joyce G. Small, Madeleine C. Kolar & Jeffrey J. Kellams. (2004) Quetiapine in schizophrenia: onset of action within the first week of treatment. Current Medical Research and Opinion 20:7, pages 1017-1023.
Read now
Read now
Celso Arango & Julio Bobes. (2004) Managing acute exacerbations of schizophrenia: focus on quetiapine. Current Medical Research and Opinion 20:5, pages 619-626.
Read now
Read now
Articles from other publishers (23)
Rezaul Khandker, Jason Shepherd, Farid Chekani, Zaina Qureshi, Hollie Bailey, Mia Berry, Jack Wright & Lucy Massey. (2022) Atypical Treatment Switches in Schizophrenia Patients: Drivers and Associated Outcomes. Neuropsychiatric Disease and Treatment Volume 18, pages 1057-1067.
Crossref
Crossref
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
1
224
.
Juan de Dios Molina, Javier Quintero, Eduardo García-Laredo, Francisco López-Muñoz, Javier Correas-Lauffer, Eduardo Barbudo, Antonio Ceverino, Carlos Mur & E. Garcia-Resa. (2020) Cognitive Effects of Combined Amisulpride and Quetiapine Treatment in Patients With Refractory Schizophrenia: A Naturalistic, Prospective Study. American Journal of Therapeutics 27:4, pages e346-e355.
Crossref
Crossref
Cvetka Bačar Bole, Mitja Pišlar, Metka Šen, Rok Tavčar & Aleš Mrhar. (2017) Switching antipsychotics: Results of 16-month non-interventional, prospective, observational clinical research of inpatients with schizophrenia spectrum disorders. Acta Pharmaceutica 67:1, pages 99-112.
Crossref
Crossref
Andreas Roussidis, Christina Kalkavoura, Dimos Dimelis, Afroditi Theodorou, Ina Ioannidou, Eleytherios Mellos, Triantafyllia Mylonaki, Areti Spyropoulou & Andreas Yfantis. (2013) Reasons and clinical outcomes of antipsychotic treatment switch in outpatients with schizophrenia in real-life clinical settings: the ETOS observational study. Annals of General Psychiatry 12:1, pages 42.
Crossref
Crossref
Eirik Kjelby, Hugo A Jørgensen, Rune A Kroken, Else-Marie Løberg & Erik Johnsen. (2011) Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. BMC Psychiatry 11:1.
Crossref
Crossref
Javier Quintero, Eduardo Barbudo, Juan D. Molina, Carlos Mur, Antonio Ceverino, Eloy Garcia-Resa & Javier Correas Lauffer. (2011) The Effectiveness of the Combination Therapy of Amisulpride and Quetiapine for Managing Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology 31:2, pages 240-242.
Crossref
Crossref
Tunde Apantaku-Olajide, Abid Khattak & Peter Whitty. (2014) Combined antipsychotic use in a community rehabilitation psychiatric service. Irish Journal of Psychological Medicine 27:3, pages 138-140.
Crossref
Crossref
Didier Meulien, Karin Huizar & Martin Brecher. (2010) Safety and tolerability of once‐daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double‐blind, placebo‐controlled studies. Human Psychopharmacology: Clinical and Experimental 25:2, pages 103-115.
Crossref
Crossref
David Taylor, Carol Paton & Shitij Kapur. 2009. The Maudsley Prescribing Guidelines, Tenth Edition. The Maudsley Prescribing Guidelines, Tenth Edition
9
122
.
Diego Novick, Josep Maria Haro, David Suarez, João Marques-Teixeira & Dieter Naber. (2008) Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study. International Clinical Psychopharmacology 23:4, pages 203-208.
Crossref
Crossref
Leonardo Cortese, Michael P. Caligiuri, Richard Williams, Peter Schieldrop, Rahul Manchanda, Ashok Malla & Raj Harricharan. (2008) Reduction in Neuroleptic-Induced Movement Disorders After a Switch to Quetiapine in Patients With Schizophrenia. Journal of Clinical Psychopharmacology 28:1, pages 69-73.
Crossref
Crossref
Subramoniam MadhusoodananOlivera Bogunovic. (2016) Switching Elderly Patients With Dementia From Risperidone to Quetiapine. American Journal of Alzheimer's Disease & Other Dementiasr 21:3, pages 169-174.
Crossref
Crossref
Rajiv Tandon, Ronald N. Marcus, Elyse G. Stock, Linda C. Riera, Dusan Kostic, Miranda Pans, Robert D. McQuade, Margaretta Nyilas, Taro Iwamoto & David T. Crandall. (2006) A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophrenia Research 84:1, pages 77-89.
Crossref
Crossref
Peter J. Weiden. (2005) Switching antipsychotics: an updated review with a focus on quetiapine. Journal of Psychopharmacology 20:1, pages 104-118.
Crossref
Crossref
Ilkka Larmo, André de Nayer, Elmar Windhager, Irmansyah, Bernhard Lindenbauer, Hans Rittmannsberger, Thomas Platz, A. Martin Jones & Charles Altman. (2005) Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone. Human Psychopharmacology: Clinical and Experimental 20:8, pages 573-581.
Crossref
Crossref
Monika Edlinger, Susanne Baumgartner, Nadja Eltanaihi-Furtm??ller, Martina Hummer & W Wolfgang Fleischhacker. (2005) Switching Between Second-Generation Antipsychotics. CNS Drugs 19:1, pages 27-42.
Crossref
Crossref
Miho Tada, Kiyoharu Shirakawa, Nobuya Matsuoka & Seitaro Mutoh. (2004) Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Psychopharmacology 176:1, pages 94-100.
Crossref
Crossref
Sean W Flynn. (2004) Improvement of Torticollis with Quetiapine in a Schizophrenia Patient. The Canadian Journal of Psychiatry 49:2, pages 152-152.
Crossref
Crossref
Susan M Cheer & Antona J Wagstaff. (2004) Quetiapine. CNS Drugs 18:3, pages 173-199.
Crossref
Crossref
Siegfried Kasper. (2004) Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depression and Anxiety 20:1, pages 44-47.
Crossref
Crossref
W. Wolfgang Fleischhacker. (2020) Second-generation antipsychotics: are their similarities greater than their differences?. European Psychiatry 18:S2, pages 38s-45s.
Crossref
Crossref
. (2003) Current awareness in human psychopharmacology. Human Psychopharmacology: Clinical and Experimental 18:6, pages 499-506.
Crossref
Crossref